Natera has developed Signatera, a personalized ctDNA test for molecular residual disease detection and recurrence monitoring. Signatera's tumor-informed test has been validated in multiple solid tumors including melanoma for immunotherapy response monitoring. Dive deeper at www.natera.com/oncology
Contact:
Jessica Hermansen
E-mail - jhermansen@natera.com
Signatera Standing Order Sheet »
